40.16

0.32% -0.13

Pre-market: 40.90 0.74 +1.84%

Revolution Medicines Inc (RVMD)

Overview News Price History Option Chain Financials Why RVMD Down? Discussions Forecast

Revolution Medicines Inc stock is traded at $40.16, with a volume of 1.71M. It is down -0.32% in the last 24 hours and down -8.85% over the past month. Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Previous Close:

$40.29

Open:

$40.5

24h Volume:

1.71M

Relative Volume:

1.08

Market Cap:

$7.42B

Revenue:

$29.52M

Net Income/Loss:

$-567.06M

P/E Ratio:

-10.97

EPS:

-3.66

Net Cash Flow:

$-551.11M

1W Performance:

+0.83%

1M Performance:

-8.85%

6M Performance:

-12.96%

1Y Performance:

+49.13%

1-Day Range:

$39.36

$40.59

1-Week Range:

$39.36

$41.40

52-Week Range:

$26.56

$62.40

Revolution Medicines Inc Stock (RVMD) Company Profile

Name

Revolution Medicines Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

415-766-3638

Address

700 SAGINAW DR, REDWOOD CITY, CA

Employee

490

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

RVMD's Discussions on Twitter

Compare RVMD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVMD Revolution Medicines Inc	40.16	7.42B	29.52M	-567.06M	-551.11M	-3.66
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-16-24	Reiterated	Needham	Buy
Jul-12-24	Initiated	Barclays	Overweight
Jul-08-24	Initiated	Jefferies	Buy
Apr-12-24	Reiterated	Needham	Buy
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-11-24	Initiated	Piper Sandler	Overweight
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy
Jan-04-24	Initiated	Wedbush	Outperform
Nov-16-23	Initiated	Raymond James	Outperform
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-14-22	Initiated	Needham	Buy
Oct-21-22	Initiated	Oppenheimer	Outperform
May-20-22	Initiated	BofA Securities	Neutral
Mar-01-22	Upgrade	Stifel	Hold → Buy
Sep-23-21	Initiated	Stifel	Hold
Aug-12-21	Downgrade	Goldman	Buy → Neutral
May-18-21	Initiated	Goldman	Buy
May-21-20	Initiated	H.C. Wainwright	Buy
Mar-09-20	Initiated	Cowen	Outperform
Mar-09-20	Initiated	Guggenheim	Buy
Mar-09-20	Initiated	JP Morgan	Neutral

View All

Revolution Medicines Inc Stock (RVMD) Latest News

Jan 19, 2025

Sandy Cove Advisors LLC Acquires Shares of 42,008 Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat

Jan 19, 2025

Jan 18, 2025

Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround - MSN

Jan 18, 2025

Is Revolution Medicines, Inc. (RVMD) the Best Russell 2000 Stock to Invest in According to Analysts? - Insider Monkey

Jan 18, 2025

Revolution Medicines' SWOT analysis: stock poised for growth amid clinical trials - MSN

Jan 18, 2025

Jan 17, 2025

Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN

Jan 17, 2025

Revolution Medicines (NASDAQ:RVMD) Trading Down 4.6%Should You Sell? - MarketBeat

Jan 17, 2025

Certain Restricted Stock Units of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025. - Marketscreener.com

Jan 17, 2025

(RVMD) Trading Advice - Stock Traders Daily

Jan 17, 2025